Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment.
This article describes the incidence of sexual dysfunction in 30 patients subjected to long-term treatment by paroxetine in dependence on the P 450 CYP 2D6 isoenzyme metabolic status. Measured on the Arizona Sexual Experience Scale (ASEX; McGahuey, Delgado, & Gelenberg, 1999), the incidence of sexual dysfunction in patients converted to CYP 2D6 poor metabolizers was markedly higher compared with patients who had no history of such conversion, a difference that reached the level of statistical significance. Our article discusses the incidence of sexual dysfunction in connection with reduced CYP 2D6 capacity.
Zourková
Alexandra
A
Department of Psychiatry, Masaryk University, Brno, 63900, Czech Republic. zourek@kralovopolska.cz
Hadasová
Eva
E
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D018153:Czech Republic / Q000453:epidemiology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007989:Libido / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000175:diagnosis / Q000201:enzymology / Q000453:epidemiology
D018687:Antidepressive Agents, Second-Generation; D019389:Cytochrome P-450 CYP2D6; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors